Melbourne, Nov 28, 2008 (ABN Newswire) - Biota Holdings Limited (ASX:BTA)(PNK:BTAHY) announced today the appointment of Mr Richard Hill as a non executive Director.
Biota Chairman, John Grant, said that Mr Hill is an experienced director of mid sized Australian public companies and brings extensive investment banking and legal skills to the Board.
Mr Hill is currently Chairman of Sirtex Medical Limited and Calliden Group Limited and a director of Pelorus Property Group Ltd. He was a founding partner of Hill Young & Associates and formerly held a number of senior executive positions in Hong Kong and New York with Wardley Holdings Limited, a wholly owned subsidiary of Hong Kong & Shanghai Banking Corporation. He is an Attorney in New York State, USA.
Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza.
Biota research breakthroughs have included a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease, licensed to AstraZeneca and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, Biota has a key partnership with Daiichi-Sankyo for the development of second generation influenza antivirals.
Relenza(TM) is a registered trademark of the GlaxoSmithKline group of companies. *Further information available at http://www.biota.com.au
Biota Holdings Limited
